Regenerative Medical Solutions Inc
Chicago, IL · Founded 2011 · CIK 0001579613 · Biotech · Private
Insulin-producing beta-like cells derived from genetically modified iPSCs with integrated safety mechanism for diabetes treatment
regenmedsolutions.com →- Grants
- $4.3M
- 11 awards
- Sector median: 1
- Raised
- $7.0M
- 5 Form D · Aug 2023
- 37 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 8
- 5 granted · 3 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20122014201620182020202220242026
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $850,000 | |
| Private capital raised | Form D · SEC | $595,000 | |
| Private capital raised | Form D · SEC | $375,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Human induced pluripotent stem cell-derived beta-cells for drug and toxicity testing | $699,155 | |
| Federal grant | Department of Health and Human Services · Phase I · Diabetes drug screening platforms using patient pancreatic islet-like cells generated from induced pluripotent stem cells | $224,930 | |
| Federal grant | Department of Health and Human Services · Phase II · Human induced pluripotent stem cell-derived beta-cells for drug and toxicity testing | $800,794 | |
| Federal grant· 1 of 4 same day | Department of Health and Human Services · Phase I · Engineered pancreatic endocrine cells that report beta cell toxicity for use in high throughput screening applications | $217,389 | |
| Federal grant· 2 of 4 same day | Department of Health and Human Services · Phase I · Engineered pancreatic endocrine cells that report beta cell toxicity for use in high throughput screening applications | $217,389 | |
| Federal grant· 3 of 4 same day | Department of Health and Human Services · Phase I · Development of a rapid and inexpensive luciferase-based high throughput screening assay to identify compounds that alter pancreatic β cell function | $224,964 | |
| Federal grant· 4 of 4 same day | Department of Health and Human Services · Phase I · Development of a rapid and inexpensive luciferase-based high throughput screening assay to identify compounds that alter pancreatic β cell function | $224,964 | |
| Private capital raised | Form D · SEC | $181,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of a safer stem cell-based diabetes therapy via suicide gene-mediated ablation of proliferative cells | $259,578 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of a safer stem cell-based diabetes therapy via suicide gene-mediated ablation of proliferative cells | $259,578 | |
| Federal grant | Department of Health and Human Services · Phase I · Evaluation of a beta cell replacement therapy combined product that avoids the need for immunosuppression via localized induction of immune tolerance | $274,984 | |
| Private capital raised | Form D · SEC | $5,000,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of a safer stem cell-based diabetes therapy via suicide gene-mediated ablation of proliferative cells | $915,136 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1863 | Bit Global Digital Asset Management Co., Ltd. | — | — |
| 1864 | 3D Bio Holdings, Inc. | — | $7.8M |
| 1865 | Tetragenetics, Inc. | — | $7.1M |
| 1866 | Regenerative Medical Solutions Inc | — | $7.0M |
| 1867 | Angarus Therapeutics, Inc. | — | $6.9M |
| 1868 | Evoke Pharma Inc | — | $6.0M |
| 1869 | Kiniksa Pharmaceuticals | — | $5.9M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Gary GormanDirector
- Thomas JoyceExecutive Officer
- Anthony KoltonDirector · Executive Officer
- Jon Odorico, MD, FACSDirector
- Guy TagliaviaExecutive Officer
Patents
- Compositions And Methods For Differentiating Stem Cells Into Cell Populations Comprising Beta-like Cellsgranted
- Compositions And Methods For Differentiating Stem Cells Into Cell Populations Comprising Beta-like Cellsgranted
- Markers For Differentiation Of Stem Cells Into Differentiated Cell Populationsapplication
- Markers For Differentiation Of Stem Cells Into Differentiated Cell Populationsgranted
- Compositions And Methods For Differentiating Stem Cells Into Cell Populations Comprising Beta-like Cellsgranted
- Compositions And Methods For Differentiating Stem Cells Into Cell Populations Comprising Beta-like Cellsgranted
- Compositions And Methods For Differentiating Stem Cells Into Cell Populations Comprising Beta-like Cellsapplication
- Markers For Differentiation Of Stem Cells Into Differentiated Cell Populationsapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.